Shots:

• Merck signed a definitive merger agreement to acquire Harpoon to enhance its oncology pipeline with Harpoon’s portfolio of novel T-cell engagers developed through the company’s TriTAC & ProTriTAC platform
• The acquisition includes Harpoon’s lead asset HPN328, a T-cell engager targeting DLL3, currently being evaluated in a P-I/II clinical trial for safety, tolerability & PK as monotx. in patient with advanced cancers associated with expression of DLL3 incl. SCLC. Harpoon’s pipeline also includes HPN217 & HPN601
• Under the terms of the agreement, Merck will acquire all outstanding shares of Harpoon for a price per share of $23.00 in cash for a total equity value of $680M. The transaction is expected to close by H1’24

Ref: Merck | Image: Harpoon Therapeutics

Related News:- Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com